Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Mukkada VA, Gupta SK, Gold BD, Dellon ES, Collins MH, Katzka DA, Falk GW, Williams J, Zhang W, Boules M, Hirano I, Desai NK. Mukkada VA, et al. Among authors: desai nk. J Pediatr Gastroenterol Nutr. 2023 Dec 1;77(6):760-768. doi: 10.1097/MPG.0000000000003948. Epub 2023 Sep 18. J Pediatr Gastroenterol Nutr. 2023. PMID: 37718471 Free PMC article.
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
Hirano I, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Desai NK, Lan L, Williams J, Dellon ES; ORBIT1/SHP621-301 Investigators. Hirano I, et al. Among authors: desai nk. Clin Gastroenterol Hepatol. 2022 Mar;20(3):525-534.e10. doi: 10.1016/j.cgh.2021.04.022. Epub 2021 Apr 19. Clin Gastroenterol Hepatol. 2022. PMID: 33887475 Free article. Clinical Trial.
Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension.
Dellon ES, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Goodwin B, Eisner JD, Lan L, Desai NK, Williams J, Hirano I; ORBIT2/SHP621-302 Investigators. Dellon ES, et al. Among authors: desai nk. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1488-1498.e11. doi: 10.1016/j.cgh.2021.06.020. Epub 2021 Jun 26. Clin Gastroenterol Hepatol. 2022. PMID: 34182150 Free article. Clinical Trial.
Reply.
Hirano I, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Desai NK, Lan L, Williams J, Dellon ES. Hirano I, et al. Among authors: desai nk. Clin Gastroenterol Hepatol. 2022 May;20(5):1189-1190. doi: 10.1016/j.cgh.2021.06.033. Epub 2021 Jun 29. Clin Gastroenterol Hepatol. 2022. PMID: 34214677 No abstract available.
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1-3 clinical trials.
Hirano I, Dellon ES, Gupta SK, Katzka DA, Collins MH, Wojtowicz AM, Terreri B, Zhang W, Boules M, Bhatia S, Desai NK. Hirano I, et al. Among authors: desai nk. Aliment Pharmacol Ther. 2023 May;57(10):1117-1130. doi: 10.1111/apt.17430. Epub 2023 Mar 8. Aliment Pharmacol Ther. 2023. PMID: 36890134 Clinical Trial.
Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis.
Dellon ES, Collins MH, Katzka DA, Mukkada VA, Falk GW, Zhang W, Goodwin B, Terreri B, Boules M, Desai NK, Hirano I. Dellon ES, et al. Among authors: desai nk. Therap Adv Gastroenterol. 2024 Dec 23;17:17562848241307602. doi: 10.1177/17562848241307602. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39735351 Free PMC article.
124 results